Table 7.
Summary of influenza A H1N1 haemagglutination inhibition assay.
| High-Dose (n = 12) | Low-Dose (n = 11) | Placebo (n = 6) | p-Value 1+ | p-Value 2+ | p-Value 3+ | p-Value 4 | |
|---|---|---|---|---|---|---|---|
| Day 0 (pre-dose) | 320 (160–640) | 320 (80–640) | 160 (80–280) | 0.13 | 0.93 | 0.06 | 0.40 |
| Day 28 (pre-dose) | 640 (320–1280) | 320 (160–640) | 240 (160–800) | 0.21 | 0.29 | 0.36 | 0.34 |
| Fold-increase | 2 (1–2) | 1 (1–2) | 1.5 (1–5.5) | 0.75 | 0.10 | 0.99 | 0.24 |
High-dose: DelNS1-nCoV-RBD LAIV (1 × 107.7 EID50/dose) in 0.2 mL. Low-dose: DelNS1-nCoV-RBD LAIV (1 × 107 EID50/dose) in 0.2 mL. Placebo: inert excipients/ dose in 0.2 mL. p-value 1: High-dose vs. Placebo. p-value 2: Low-dose vs. Placebo. p-value 3: High-dose vs. Low-dose. + Mann-Whitney U test. p-value 4: one-way ANOVA, comparison of three groups. HAI: haemagglutination inhibition assay; IQR: interquartile range. Data were median HAI titre (IQR).